APTEVO THERAPEUTICS INC. (NASDAQ:APVO) Files An 8-K Regulation FD Disclosure

50

APTEVO THERAPEUTICS INC. (NASDAQ:APVO) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

Aptevo Therapeutics Inc. (the “Company”) has prepared presentation materials, which it intends to present at the BIO International Convention held in San Diego, California. A copy of the presentation materials to be used in the presentations is attached hereto as Exhibit 99.1.  

The information in this Current Report on Form 8-K, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

See Exhibit Index attached hereto.



Aptevo Therapeutics Inc. Exhibit
EX-99.1 2 apvo-ex991_72.htm EX-99.1 apvo-ex991_72.pptx.htm Developing Next-Generation ADAPTIRTM Molecules From the Bench to the Clinic BIO International 19-21 June,…
To view the full exhibit click here
About APTEVO THERAPEUTICS INC. (NASDAQ:APVO)

Aptevo Therapeutics Inc. is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform. The Company has approximately four products in the areas of hematology and infectious diseases, as well as various investigational-stage product candidates in immuno-oncology. The Company’s investigational-stage product candidates include MOR209/ES414, ES210, ES425, Otlertuzumab and 5E3. Its technology can produce monospecific and multispecific immunotherapeutic proteins that bind to various targets. The Company’s marketed products are WinRho SDF (Rho(D) Immune Globulin Intravenous (Human)), HepaGam B (Hepatitis B Immune Globulin Intravenous (Human)), VARIZIG (Varicella Zoster Immune Globulin (Human)), and IXINITY (coagulation factor IX (recombinant)).

An ad to help with our costs